glp 1 rhabdomyolysis GLP-1-based therapies for type 2 diabetes: from single, dual and triple Emerging Frontiers in GLP-1 Therapeutics:

We want you to have these strength metrics above this range

| Co-prescribed Drug | Interaction Pathway | Effect on Co-Drug | Severity | Clinical Action | |---|---|---|---|---| | Warfarin | Hepatic CYP2C9 induction (GCGR) | Reduced anticoagulant effect

Experienced providers help bridge that gap with dose titration, side effect management, adherence support, and ongoing monitoring

Retatrutide has a higher overall adverse event burden (6-10% discontinuation), partly because of the unique dysesthesia side effect at higher doses

It was originally developed as a diabetes medication (Ozempic) before the weight loss applications became clear